Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Ansichten
• 07/18/23
0
0
Einbetten
administrator
Abonnenten
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Zeig mehr
Facebook Kommentare
SORT BY-
Beste Kommentare
-
Neueste Kommentare